M&A

Euroeyes buys out $4.98M minority stakes in three Chinese clinics

What's the deal? Euroeyes International Eye ClinicDealroom has a profile for this one. Try Dealroom → (01846) will pay US$4.57M to acquire 30% stakes in three target companies in Shanghai, Guangzhou, and Beijing. Its subsidiaries signed the share-transfer agreements on November 16, 2026, with seller Shanghai Lingrui Enterprise Development.

What changes? After completion, the seller will no longer hold any equity in the three companies. The Shanghai and Guangzhou clinics become wholly owned subsidiaries, while the Beijing clinic will be fully held by Euroeyes subsidiaries. The three companies will also carry out a capital reduction to cancel the corresponding equity.

Why now? The move tightens Euroeyes' grip on its Chinese operations after a year of large-scale expansion. In July 2026, it completed the acquisition of Dutch eye-care group FYEODealroom has a profile for this one. Try Dealroom → at an enterprise value of about €135 million, a deal it said would widen its combined revenue base by roughly 65% on a pro forma basis.

What could go wrong? The expansion has brought short-term pressure. Euroeyes flagged a swing to a loss in the first half of 2026, citing acquisition costs and losses at its Swiss operations, with FYEO's results only consolidating in the second half.

The small print: The transaction constitutes a discloseable and connected transaction. It has been approved by the board and is exempt from shareholder approval.

The signal: Buying out minority partners is a classic consolidation play, giving Euroeyes full control of profits and decision-making across its main mainland clinics as it integrates a much larger European footprint.

Read more: sohu.com

Image credit: "Naval Hospital Jacksonville Ophthalmology Clinic 221026-N-QA097-033" by NavyMedicine, public domain (Public Domain Mark 1.0)

More top stories